RESEARCH DIGEST / STABLE GASTRIC PENTADECAPEPTIDE
BPC-157 is a stable gastric pentadecapeptide whose tissue-repair research is most consistently tied to angiogenesis.
A panel-by-panel reading of the BPC-157 record: the multi-tissue preclinical evidence, the three small human pilots, the animal pharmacokinetics, and the current FDA 503A status — every quantitative claim cited.
What Is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a Body Protection Compound found in human gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, its molecular formula C62H98N16O22, and its molecular weight about 1419.53 Da. Researchers describe it as a stable gastric pentadecapeptide — a cytoprotective, regenerative research peptide — and it is not an approved drug.
Across three decades of preclinical work, one finding recurs: BPC-157 accelerates tissue repair, and the repair effect is most consistently linked to angiogenesis, the formation of new blood vessels. In a fully transected rat Achilles tendon, BPC-157 improved biomechanical, functional, microscopic, and macroscopic recovery and stimulated tendocyte outgrowth in vitro [1]. In rat gastric ulcers, intramuscular dosing inhibited ulcer formation by 45.7-65.6% at the higher doses tested [4]. The mechanism that ties these together — VEGFR2 up-regulation feeding Akt and eNOS signaling — is documented on the BPC-157 angiogenesis page [3].
What the literature does not yet have is large human evidence. As of 2025 reviews, only three small human pilot studies exist, and rigorous large-scale controlled trials are lacking [8]. BPC-157 is a research peptide with a broad, reproducible animal record and a thin human one. This site reads both, panel by panel, and cites each claim to its source.
BPC-157 Peptide: Identity, Sequence, and Origin
The BPC-157 peptide is a synthetic fragment, not a naturally circulating molecule. It is derived from a partial sequence of the Body Protection Compound identified in human gastric juice, and the synthesized 15-residue peptide is the stable form studied in the laboratory [5]. Its identifiers are settled: CAS 137525-51-0, PubChem CID 108101, and the sequence GEPPPGKPADDAGLV. It is often supplied as the acetate salt.
The descriptor "stable gastric pentadecapeptide" is the authors' own, and it is load-bearing. BPC-157 is reported to remain stable in human gastric juice, which is the basis for interest in oral and peroral routes [5]. Synonyms appearing in the literature include Pentadecapeptide BPC 157, PL 14736, PLD-116, and PL-10 — the last three are industrial development designations under which the peptide entered early clinical work.
What does BPC-157 do in the body?
In animal models, BPC-157 acts as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis through VEGFR2-Akt-eNOS signaling [3]. It has accelerated healing across tendon, ligament, bone, muscle, gut, and vascular models, and rat studies report protection of distant organs — liver, kidney, and lung — in acute pancreatitis [13].
The pharmacokinetic picture is short and well-defined in animals: a 2022 study in rats and dogs reported linear pharmacokinetics and an elimination half-life under 30 minutes, with the peptide breaking down rapidly into small fragments that enter normal amino-acid metabolism [2]. That brevity is why animal studies dose once daily across a healing course rather than as a single intervention. These are animal-model findings; the human dataset is limited to three small pilots [8]. The VEGFR2-Akt-eNOS mechanism page sets out the pathway in full.
How is BPC-157 made?
BPC-157 is a synthetic peptide. It is assembled as the 15-amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a partial sequence drawn from a Body Protection Compound found in human gastric juice. The peptide itself is a stable synthetic fragment rather than a peptide that circulates naturally in the body. A 2025 first-in-human IV safety pilot administered it by infusion; most of the record, however, is preclinical [7].
Read the Record by Panel
The BPC-157 record divides cleanly into a few color-keyed reading panels. The preclinical research findings panel collects the multi-tissue evidence — tendon, gastric ulcer, organ protection — and the three human pilots. The BPC-157 angiogenesis panel sets out the unifying VEGFR2-Akt-eNOS mechanism. The research dosing panel reads the doses, routes, and short animal half-life exactly as the studies express them, with no human protocol implied. The BPC-157 legal status panel states the current FDA 503A position, present-tense and cited. And the frequently asked questions panel answers the safety, timing, and comparison questions readers actually ask, each one cited where it makes a quantitative claim.